Back to Search Start Over

HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registry.

Authors :
Calafat M
Suria C
Mesonero F
de Francisco R
Caballero CY
Peña L
Hernández-Camba A
Marcé A
Gallego B
Martín-Vicente N
Rivero M
Iborra M
Guerra I
Carrillo-Palau M
Madero L
Burgueño B
Monfort D
Torres G
Teller M
Ferrer Rosique JÁ
Villaamil PV
Roig C
Ponferrada-Diaz A
Glaría EB
Zabana Y
Gisbert JP
Busquets D
Alcaide N
Camps B
Legido J
González-Vivo M
Bosca-Watts MM
Pérez-Martínez I
Deza DC
Guardiola J
Hernández LA
Navarro M
Gargallo-Puyuelo CJ
Cañete F
Mañosa M
Domènech E
Source :
The American journal of gastroenterology [Am J Gastroenterol] 2024 Jul 15. Date of Electronic Publication: 2024 Jul 15.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Background: The coexistence of human immunodeficiency virus (HIV) infection and inflammatory bowel disease (IBD) is uncommon. Data on the impact of HIV on IBD course and its management is scarce.<br />Aim: To describe the IBD phenotype, therapeutic requirements and prevalence of opportunistic infections (OI) in IBD patients with a coexistent HIV infection.<br />Methods: Case-control, retrospective study including all HIV positive patients diagnosed with IBD in the ENEIDA registry. Patients with positive HIV serology (HIV-IBD) were compared to controls (HIV seronegative), matched 1:3 by year of IBD diagnosis, age, gender and type of IBD.<br />Results: A total of 364 patients (91 HIV-IBD and 273 IBD controls) were included. In the whole cohort, 58% had ulcerative colitis (UC), 35% had Crohn's disease (CD) and 7% were IBD unclassified. The HIV-IBD group presented a significantly higher proportion of proctitis in UC and colonic location in CD but fewer extraintestinal manifestations than controls. Regarding treatments, non-biological therapies (37.4% vs. 57.9%; P=0.001) and biologicals (26.4% vs. 42.1%; P=0.007), were used less frequently among patients in the HIV-IBD group. Conversely, HIV-IBD patients developed more OI than controls regardless of non-biological therapies use. In the multivariate analysis, HIV infection (OR 4.765, 95%CI 2.48-9.14; P<0.001) and having ≥1 comorbidity (OR 2.445, 95%CI 1.23-4.85; P=0.010) were risk factors for developing OI, while CD was protective (OR 0.372, 95%CI 0.18-0.78;P=0.009).<br />Conclusions: HIV infection appears to be associated with a less aggressive phenotype of IBD and a lesser use of non-biological therapies and biologicals but entails a greater risk of developing OI.<br /> (Copyright © 2024 by The American College of Gastroenterology.)

Details

Language :
English
ISSN :
1572-0241
Database :
MEDLINE
Journal :
The American journal of gastroenterology
Publication Type :
Academic Journal
Accession number :
39008547
Full Text :
https://doi.org/10.14309/ajg.0000000000002965